| HOME >> BIOLOGY >> TECHNOLOGY |
TAI'AN, Shandong, China, Sept. 10 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ("China Biologic," or the "Company"), one of the leading plasma-based pharmaceutical companies in the People's Republic of China ("PRC"), operating through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. ("Taibang") and Chongqing Dalin Biologic Technologies Co., Ltd. ("Dalin") and its equity investment in Xi'an Huitian Blood Products Co., Ltd. ("Huitian"), today announced that the Company's management team will attend the upcoming Susquehanna International Group of Companies ("SIG") 3rd Annual Beijing Management Summit, and the Company's CEO, Mr. Colin Zhao, and newly appointed Director of Research and Development, Dr. Vincent Xie, will participate on the China Pharma-Biotech Panel at the conference.
The 3rd Annual Beijing Management Summit is a two-day conference that brings together executives from public and private companies based in China and other emerging Asian economies. The event will showcase leading companies in the Chinese Consumer, Health Care, Internet, and Technology sectors, as well as companies in the IT Services/Outsourcing and Financial Technologies sectors. The event format will consist of one-on-one meetings and company presentations.
The date and location of China Biologic's one-on-one meetings and the
China Pharma-Biotech Panel at the SIG 3rd Annual Beijing Management Summit are
as follows:
Date: September 16 - 17, 2009
Location: The Grand Hyatt Beijing Hotel
1 East Chang An Avenue
Beijing 100738
Panel Schedule: China Pharma-Biotech Panel
September 16, 2009
1:05-2:10 PM Beijing Time
Drawing Room IV
China Biologic will be available for one-on-one meetings with a
'/>"/>
| SOURCE China Biologic Products, Inc. Copyright©2009 PR Newswire. All rights reserved |